Vistagen Therapeutics (VTGN) Enterprise Value (2012 - 2026)

Vistagen Therapeutics has disclosed Enterprise Value across 15 years of filings, most recently posting -$21.5 million for Q2 2026.

• In Q2 2026, Enterprise Value fell 1083.21% year-over-year to -$21.5 million; the TTM figure through Jun 2026 stood at -$21.5 million (down 1083.21% YoY), while the FY2026 annual figure was -$22.0 million, down 190.14% from the prior year.
• Enterprise Value came in at -$21.5 million for Q2 2026 at Vistagen Therapeutics, up from -$22.0 million in the prior quarter.
• In the past five years, Enterprise Value ranged from a high of $188.2 million in Q1 2022 to a low of -$35.6 million in Q4 2025.
• Average Enterprise Value over 5 years is $15.5 million, with a median of -$3.8 million recorded in 2022.
• Year-over-year, Enterprise Value surged 557.79% in 2025 and plunged 1083.21% in 2026.
• Over 5 years, Enterprise Value stood at -$4.3 million in 2022, then surged by 384.18% to $12.3 million in 2023, then sank by 127.76% to -$3.4 million in 2024, then plunged by 942.5% to -$35.6 million in 2025, then surged by 39.58% to -$21.5 million in 2026.
• Per Business Quant data, the three most recent Enterprise Value figures were -$21.5 million in Q2 2026, -$22.0 million in Q1 2026, and -$35.6 million in Q4 2025.